Omschrijving

To effectively treat patients diagnosed with drug-resistant (DR) tuberculosis (TB) and protect the population from further transmission of this infectious disease, an uninterrupted supply of quality-assured (QA), second-line anti-TB drugs (SLDs) is necessary. Patients diagnosed with multidrug-resistant tuberculosis (MDR TB)-a disease caused by strains of Mycobacterium tuberculosis (M.tb.) resistant to two primary TB drugs (isoniazid and rifampicin)-face lengthy treatment regimens of 2 years or more with daily, directly observed treatment (DOT) with SLDs that are less potent, more toxic, and more expensive than those used to treat drug-susceptible TB. From 2000 to 2009, only 0.2-0.5 percent of the estimated 5 million MDR TB cases globally were treated with drugs of known quality and in prog

Kenmerken

Artikelnummer9200000021876118
EAN9780309265959
CategorieEducational Books
ProductgroepBoeken
SegmentTextual/Printed/Reference Materials
Prijs Nederland€ 50,99
Prijs België€ 50,99
Verzendkosten NLGratis
Verzendkosten BEGratis
Levertijd NederlandOver 57 dagen
Levertijd BelgiëOver 57 dagen
VerkoperPartner

Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis bestellen bij snelkeus

Koop Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis van Onbekend online in de categorie Educational Books. Prijs € 50,99, levering in Nederland · Over 57 dagen.